Yorktown Management & Research Company’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Yorktown Management & Research Company’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-137,300	Closed	-$1.15M	–	275
2021 Q4	$1.15M	Buy	137,300 +24,100	+21%	+$199K	0.77%	19
2021 Q3	$841K	Buy	113,200 +56,600	+100%	+$351K	0.63%	28
2021 Q2	$385K	Buy	56,600 +7,400	+15%	+$61.5K	0.3%	141
2021 Q1	$505K	Hold	49,200	–	–	0.42%	72
2020 Q4	$344K	Sell	49,200 -2,000	-4%	-$15.6K	0.31%	157
2020 Q3	$418K	Buy	51,200 +8,200	+19%	+$50.8K	0.39%	91
2020 Q2	$297K	Buy	+43,000	New	+$232K	0.27%	193

Other funds holding JNCE

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Yorktown Management & Research Company's JNCE Position: Q1 2022 in Review

Yorktown Management & Research Company sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 137,300 shares — an estimated $1.15M sold.

Yorktown Management & Research Company first reported a position in JNCE in Q2 2020 and held it in 7 quarters. The position peaked at $1.15M in Q4 2021. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

Yorktown Management & Research Company reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Yorktown Management & Research Company sold 137,300 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.15M.
Yorktown Management & Research Company first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
Yorktown Management & Research Company's Jounce Therapeutics, Inc. Common Stock position peaked at $1.15M in Q4 2021.
113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Yorktown Management & Research Company's 13F filing for Q1 2022, filed 29 Apr 2022.